Treatment of Hyperammonemia After TIPS

First-Line Management

Lactulose should be used as the primary treatment for hyperammonemia and hepatic encephalopathy (HE) following TIPS, reducing blood ammonia levels and improving mental status in patients, according to the Journal of Hepatology guidelines 1, 2, 3
The standard approach is to titrate lactulose dosing to achieve 2-3 soft bowel movements per day, which helps reduce intestinal ammonia production and absorption, as recommended by the Journal of Hepatology 2, 3

Rifaximin should be added to lactulose therapy in cases where lactulose alone fails to control hyperammonemia and HE symptoms, or may replace lactulose in patients who cannot tolerate it, as suggested by the Journal of Hepatology 1, 2
For patients with a history of HE before TIPS placement, combination therapy with lactulose and rifaximin is strongly recommended to prevent post-TIPS HE recurrence, according to the Journal of Hepatology 1

In approximately 8% of cases, HE persists despite optimal medical treatment with lactulose and rifaximin, as reported by the Journal of Hepatology 1
For refractory cases, shunt reduction or occlusion should be considered, as recommended by the Journal of Hepatology 1, 2
After shunt reduction, HE improves or resolves in 48-100% of cases, though this may lead to recurrence of the original condition that necessitated TIPS placement, according to the Journal of Hepatology 2, 3
For patients with severe, intractable HE after TIPS that doesn't respond to medical therapy and shunt modification, liver transplantation should be rapidly considered, as suggested by the Journal of Hepatology 1

Doppler ultrasound is recommended one week after TIPS implantation in patients with prothrombotic conditions, and at 6-12 month intervals in other patients to ensure proper shunt function, as recommended by Gut 4, 5
Nutritional status assessment is important as sarcopenia is associated with increased risk of post-TIPS HE, according to the Journal of Hepatology 1

Prophylactic therapy with lactulose or rifaximin is not recommended for the prevention of post-TIPS HE according to current guidelines from the Journal of Hepatology 2, 3
Careful patient selection before TIPS placement remains the most effective strategy to prevent post-TIPS hyperammonemia, with assessment of risk factors including age, history of HE, and liver function, as recommended by Gut 6, 4
In high-risk patients, using smaller diameter stents may reduce the risk of developing HE following TIPS by limiting the portosystemic shunting effect, according to Gut 6